Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 16/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455880 | 0.88 | TFPI (0.53) | IL23RTFPIRXFP1 | |
| SCHEMBL29575493 | 0.87 | TFPI (0.46) | IL23RTFPIRXFP1 | |
| SCHEMBL29939729 | 0.87 | TFPI (0.55) | IL23RTFPIRXFP1 | |
| SCHEMBL31691755 | 0.86 | NPY4R (0.44) | PTGS1GSTK1 | |
| SCHEMBL30186434 | 0.85 | IL23R (0.44) | IL23RTFPIRXFP1 | |
| SCHEMBL30198545 | 0.84 | TFPI (0.45) | IL23RTFPIRXFP1 | |
| SCHEMBL30148472 | 0.84 | TFPI (0.47) | TFPIRXFP1 | |
| SCHEMBL30099637 | 0.84 | TFPI (0.45) | IL23RTFPI | |
| SCHEMBL30942619 | 0.84 | IL23R (0.48) | IL23RTFPIRXFP1 | |
| SCHEMBL31047157 | 0.84 | FOLH1 (0.48) | TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | IL23R 1502/4885TFPI 2394/4885RXFP1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.